Prime Medicine, Inc. Income (Loss) Attributable to Parent, before Tax
Prime Medicine, Inc. (PRME) reported Income (Loss) Attributable to Parent, before Tax of -$52.59 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossAttributableToParent · last filed 2025-08-07
- Prime Medicine, Inc. income (loss) attributable to parent, before tax for the quarter ending 2025-06-30 was -$52.59M.
- Prime Medicine, Inc. income (loss) attributable to parent, before tax for the quarter ending 2025-03-31 was -$51.89M.
- Prime Medicine, Inc. income (loss) attributable to parent, before tax for the quarter ending 2024-12-31 was -$42.28M.
- Prime Medicine, Inc. income (loss) attributable to parent, before tax for the quarter ending 2024-09-30 was -$52.52M.
- Prime Medicine, Inc. income (loss) attributable to parent, before tax for fiscal 2024 was -$195.88M.
- Prime Medicine, Inc. income (loss) attributable to parent, before tax for fiscal 2023 was -$198.41M.
- Prime Medicine, Inc. income (loss) attributable to parent, before tax for fiscal 2022 was -$122.77M.
- Prime Medicine, Inc. income (loss) attributable to parent, before tax for fiscal 2021 was -$165.85M.
| Period end | Income (Loss) Attributable to Parent, before Tax 3 month | Income (Loss) Attributable to Parent, before Tax 6 month | Income (Loss) Attributable to Parent, before Tax 9 month | Income (Loss) Attributable to Parent, before Tax 12 month |
|---|---|---|---|---|
| 2025-06-30 | -$52.59M 10-Q · filed 2025-08-07 | -$104.48M 10-Q · filed 2025-08-07 | -$146.76M derived: sum of 3 quarters · filed 2025-08-07 | -$199.28M derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | -$51.89M 10-Q · filed 2025-05-08 | -$94.17M derived: sum of 2 quarters · filed 2025-05-08 | -$146.68M derived: sum of 3 quarters · filed 2025-05-08 | -$202.15M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-12-31 | -$42.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$94.79M derived: sum of 2 quarters · filed 2025-02-28 | -$150.25M derived: sum of 3 quarters · filed 2025-08-07 | -$195.88M 10-K · filed 2025-02-28 |
| 2024-09-30 | -$52.52M 10-Q · filed 2024-11-12 | -$107.98M derived: sum of 2 quarters · filed 2025-08-07 | -$153.61M 10-Q · filed 2024-11-12 | -$219.25M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-06-30 | -$55.46M 10-Q · filed 2025-08-07 | -$101.09M 10-Q · filed 2025-08-07 | -$166.73M derived: sum of 3 quarters · filed 2025-08-07 | -$217.55M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$45.63M 10-Q · filed 2025-05-08 | -$111.27M derived: sum of 2 quarters · filed 2025-05-08 | -$162.09M derived: sum of 3 quarters · filed 2025-05-08 | -$204.44M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$65.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$116.46M derived: sum of 2 quarters · filed 2025-02-28 | -$158.81M derived: sum of 3 quarters · filed 2025-02-28 | -$198.41M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$50.82M 10-Q · filed 2024-11-12 | -$93.17M derived: sum of 2 quarters · filed 2024-11-12 | -$132.77M 10-Q · filed 2024-11-12 | -$172.24M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$42.35M 10-Q · filed 2024-08-08 | -$81.95M 10-Q · filed 2024-08-08 | -$121.42M derived: sum of 3 quarters · filed 2024-08-08 | -$150.56M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$39.60M 10-Q · filed 2024-05-10 | -$79.07M derived: sum of 2 quarters · filed 2024-05-10 | -$108.21M derived: sum of 3 quarters · filed 2024-05-10 | -$138.00M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$39.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$68.61M derived: sum of 2 quarters · filed 2024-03-01 | -$98.40M derived: sum of 3 quarters · filed 2024-03-01 | -$122.77M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$29.14M 10-Q · filed 2023-11-03 | -$58.93M derived: sum of 2 quarters · filed 2023-11-03 | -$83.30M 10-Q · filed 2023-11-03 | -$144.83M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | -$29.79M 10-Q · filed 2023-08-07 | -$54.16M 10-Q · filed 2023-08-07 | -$115.69M derived: sum of 3 quarters · filed 2023-08-07 | -$134.47M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$24.37M 10-Q · filed 2023-05-11 | -$85.90M derived: sum of 2 quarters · filed 2023-05-11 | -$104.68M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$61.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$80.31M derived: sum of 2 quarters · filed 2023-03-09 | -$165.85M 10-K · filed 2023-03-09 | |
| 2021-09-30 | -$18.78M 10-Q · filed 2022-11-14 | -$104.32M 10-Q · filed 2022-11-14 | ||
| 2020-12-31 | -$1.54M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |